Asset Intelligence / Hyperliquid Context
HIMS
Archive-backed market intelligence for HIMS: every HIPERWIRE mover article tied to this asset, plus a client-refreshed live market panel.
Live Structure
Market Status
Loading current market structure...
- Builderxyz
- Categorystock
- Tracked Marketxyz:HIMS
- Latest TweetOpen
No other live markets from this builder in the current screener.
No same-category alternatives are live in the current screener snapshot.
Archive Summary
Latest Archived Thesis
HIMS Adds 6.74% as RFK Jr. Pushes FDA to Unwind 12 Restricted Peptides
Hims & Hers extended its squeeze on April 16 after HHS Secretary Robert F. Kennedy Jr. said the FDA will pull 12 wellness peptides out of Category 2 restrictions and send them to the Pharmacy Compounding Advisory Committee for review in July. The list reads like a Hims product roadmap: BPC-157, KPV, TB-500, MOTs-C, semax, epitalon. Bank of America lifted its target to $25 from $21, pointing at the California peptide facility Hims acquired in February 2025 as ready-to-monetize capacity. Yesterday's move was a technical short squeeze with no catalyst — today's is the fundamental layer bears now have to price in.
Archive
All HIMS Mover Articles
HIMS Adds 6.74% as RFK Jr. Pushes FDA to Unwind 12 Restricted Peptides
Hims & Hers extended its squeeze on April 16 after HHS Secretary Robert F. Kennedy Jr. said the FDA will pull 12 wellness peptides out of Category 2 restrictions and send them to the Pharmacy Compounding Advisory Committee for review in July. The list reads like a Hims product roadmap: BPC-157, KPV, TB-500, MOTs-C, semax, epitalon. Bank of America lifted its target to $25 from $21, pointing at the California peptide facility Hims acquired in February 2025 as ready-to-monetize capacity. Yesterday's move was a technical short squeeze with no catalyst — today's is the fundamental layer bears now have to price in.
HIMS Squeezes Through the 200-Week Moving Average With 46% of Float Short
Hims & Hers ripped 14% on April 15 with no single headline catalyst. The setup told the story: 85 million shares short — 46% of float — and a technical breakout above the 200-week moving average that started Sunday triggered a cascade of forced covering. The stock had been coiling in a $20–$23 range after the March Novo Nordisk settlement, and the break above that range with volume turned a crowded short into a forced unwind.
How to Trade HIMS on Hyperliquid
Hims & Hers Health is the largest direct-to-consumer telehealth platform in the US, connecting millions of subscribers to licensed providers for treatments spanning weight loss, hair care, sexual health, and mental wellness. HIMS is now available as a HIP-3 perpetual futures contract on Hyperliquid, giving traders leveraged exposure to one of the most volatile healthcare stocks of 2026.
Background reading selected from this asset's symbol, builder context, and archived catalyst coverage.
HIP-3 Explained: Anyone Can Launch Hyperliquid Perps
HIP-3 lets anyone deploy a perpetual futures market on Hyperliquid — no approval needed. How builders launch markets, post stake, and earn fees.
Funding Rates Explained: A Trader's Guide (2026)
Funding rates decide if you pay or earn holding a perp position. How Hyperliquid's hourly funding works, reading rate signals, and cash-and-carry arbitrage.